Salmon DNA Polynucleotides (PDRN)

Polynucleotide (PDRN) therapy involves injecting highly purified DNA fragments — derived from salmon sperm — into the dermis to trigger the skin's own repair and collagen synthesis pathways. At Skinderm Ostrava, topical anaesthetic is applied before fine needles deposit the PDRN solution at multiple intradermal points across the face, neck, or décolletage. The treatment stimulates fibroblasts to produce new collagen and elastin, and activates the A2A adenosine receptor pathway, which accelerates tissue repair and reduces inflammation. Results build cumulatively across 3–4 sessions.

PDRN (polydeoxyribonucleotide) is extracted from the sperm of Oncorhynchus mykiss (rainbow trout) through a highly controlled purification process that removes proteins responsible for allergic reactions, leaving only the DNA backbone chains. When injected into the dermis, these polynucleotide fragments bind to adenosine A2A receptors on fibroblasts and endothelial cells. This receptor activation simultaneously triggers collagen and elastin gene expression, stimulates formation of new blood vessels (angiogenesis), and dampens local inflammatory signalling — a combination that makes PDRN unusually effective in both rejuvenation and the repair of compromised or damaged skin. At Skinderm, each session begins with the application of a topical anaesthetic cream for 20–30 minutes to ensure patient comfort. The treating physician then makes a series of intradermal microinjections across the mapped treatment area — typically the full face, neck, and décolletage, or targeted zones such as around the eyes or across scarred tissue. Sessions take 30–45 minutes. Mild redness and small injection-site papules resolve within 24 hours for most patients. The recommended protocol is 3–4 sessions separated by 2–3 weeks, which delivers a cumulative stimulatory effect: each session builds on the fibroblast activation from the previous one. The biosynthetic activity triggered by PDRN continues for months after the course completes — clinical studies report measurable collagen density improvements at 6 and 12 months post-course. This makes polynucleotide therapy particularly interesting as a long-arc anti-ageing intervention rather than a quick-result procedure. PDRN is well-tolerated across all skin types including sensitive skin, and can be combined with other modalities such as microneedling (where it is sometimes applied as a topical adjunct post-treatment), laser, or Profhilo. It is also appropriate in the periocular region where volumising agents carry more risk. Patients typically notice improved hydration, skin texture, and elasticity before the collagen-related firming effect becomes visible. Contraindications: allergy to salmon or fish products, pregnancy, nursing, active skin infection.